Pharmacological approaches to the treatment and prevention of aphasia

Aphasiology

Volumn 14, Issue 12, 2000, Pages 1163-1186

  Shisler, R J ^a   Baylis, Gordon C ^b   Frank, Elaine M ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; AMOBARBITAL; AMPHETAMINE; APTIGANEL; BROMOCRIPTINE; CHLORDIAZEPOXIDE; CITICOLINE; CLOMETHIAZOLE; DIZOCILPINE; ELIPRODIL; FIBRINOLYTIC AGENT; GM 1; GYK 152466; LUBELUZOLE; MEPROBAMATE; METHYLPHENIDATE; MONOSIALOGANGLIOSIDE; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER; NIMODIPINE; PIRACETAM; STREPTOKINASE; TIRILAZAD; TISSUE PLASMINOGEN ACTIVATOR; TOLAZOLINE; UNCLASSIFIED DRUG;

APHASIA; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CATECHOLAMINERGIC SYSTEM; CELL LOSS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE MODEL; DOSE RESPONSE; DRUG MECHANISM; DYSTONIA; GABAERGIC SYSTEM; HUMAN; HYPERTENSION; MENTAL DISEASE; NEUROPHARMACOLOGY; NONHUMAN; OXYGENATION; PHYSIOTHERAPY; REVIEW; SPEECH THERAPY; STROKE;

EID: 0034519504     PISSN: 02687038     EISSN: None     Source Type: Journal    
DOI: 10.1080/02687030050205705     Document Type: Review

References (148)

1. Pharmacotherapy for aphasia
2. Ganglioside GM1 in acute ischemic stroke. The SASS trial
3. Clinical trial of Nimodipine in acute ischemic stroke
4. Effects of citicoline combined with thrombolytic therapy in rate embolic stroke model
5. Citicoline for treatment of experimental focal ischemia: Histologic and behavioral outcome
6. Combined neuroprotection and reperfusion therapy for stroke: Effect of Lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia
7. The pharmacotherapy of aphasia: Historical perspective and directions for future research
8. Finding new drugs to treat stroke
9. Aphasia: Effect of intravenous sodium amytal
10. Observation of the use of sodium amytal in the treatment of aphasia
11. Diaspirin cross-linked hemoglobin improves neurological outcome following reversible by not irreversible CNS ischemia in rabbits
12. Therapeutic approaches in subjects with brain lesions
13. Pharmacological reduction of electrophysiological diaschisis after photothrombotic ischemia in rat neocortex
14. The role of glutamate antagonists for the treatment of CNS injury
15. Monosialoganglioside GM1 in cerebral ischemia
16. d-Amphetamine in elderly patients refractory to rehabilitation procedures
17. A randomized efficacy trial of citicoline in patients with acute ischemic stroke
18. Effects of Piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain
19. Focal cerebral ischemia in rats: Effect of hemodilution with alpha-alpha cross-linked hemoglobin on brain injury and edema
20. Focal cerebral ischemia in rats; Effect of hemodilution with alpha-alpha cross-linked hemoglobin on CBF
21. The Canadian Neurological Scale: A preliminary study in acute stroke
22. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients
23. The effect of alerting and tranquilizing drugs upon the performance of aphasic patients
24. Termination of acute stroke studies involving Selfotel treatment. ASSIST Steering Committee
25. Piracetam in Acute Stroke (PASS)
26. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group
27. Opportunities for neuroprotection
28. The Token Test: A sensitive test to detect receptive disturbances in aphasics
29. Lubeluzole protects sensorimotor function and rescues infarct size in a photochemical stroke model in rats
30. Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial
31. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial study group
32. Considerations in the design of clinical trial of neuroprotective therapy in acute stroke
33. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke
34. Duration of neuroprotective treatment for ischemic stroke
35. Effect of Piracetam on recovery and rehabilitation after stroke: A double-blind, placebo-controlled study
36. From laboratory to clinic: Noradrenergic enhancement of physical therapy for stroke or trauma patients
37. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury
38. TPA for acute ischemic stroke
39. Evolving toward effective therapy for acute ischemic stroke
40. Brain edema
41. The response of GABAergic and cholinergic neurons to transient cerebral ischemia
42. Anatomic basis of transcortical motor aphasia
43. Nimodipine and the haemodynamic and histophatologic consequences of middle cerebral artery occlusion in the rat
44. The pharmacotherapy of focal cortical ischemia in the mouse
45. Clomethiazole (Zendra) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy
46. Why do all drugs work in animals but none in stroke patients? Neuroprotective therapy
47. Rodent models of stroke limitations: What can we learn from recent clinical trials of thrombolysis?
48. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial
49. Bromocriptine treatment of nonfluent aphasia
50. Relevance of rodent models of stroke
51. Intravenous thrombolysis with recombinant Tissue Plasminogen Activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS)
52. A and glycine receptors by chlormethiazole
53. Pilot randomized trial of Tissue Plasminogen Activator in acute ischemic stroke
54. Therapeutic benefits of lubeluzole in ischemic stroke
55. Neuropharmacological therapy and motor recovery after stroke
56. The ischemic penumbra
57. Restoration of speech in severe aphasia by intravenous and oral Priscol
58. Neuroprotective therapy
59. Piracetam as an adjunct to language therapy for aphasia: A randomized double-blind placebo-controlled pilot study
60. Effects of CDP-choline on neurogenic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia
61. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with anaurysmal hemorrhage-A cooperative study in Europe and Australia
62. A randomized, double-blind, placebo-controlled trial of Nimodipine in acute ischemic hemispheric stroke
63. The performance test of activities of daily living
64. Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial
65. Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthase pathway
66. Cerestat and other NMDA antagonists in ischemic stroke
67. Sodium amytal in treatment of aphasia
68. Tissue Plasminogen Activator
69. Thrombolysis for acute stroke
70. Combination therapy protects ischemic brain in rats
71. The effects of bromocriptine of speech and language function in a man with transcortical motor aphasia
72. Functional evaluation: The Barthel Index
73. Pitfalls and advances from the international tirilazad trial in moderate and severe head injury
74. Inflammatory reaction after brain damage and prospective therapy against damage impending cerebral infarction
75. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man
76. Neurochemical sequelae of traumatic brain injury: Therapeutic implications
77. Acetylcholine and experimental brain injury
78. MK-801 reduces extensive infarction after suture middle cerebral artery occlusion in rats
79. Effects of a novel NMDA agonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI
80. Pharmacological approaches to the treatment of aphasia
81. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
82. FDA approval may be next for Citicoline
83. Tissue Plasminogen Activator for acute ischemic stroke
84. Generalized efficacy of rt-PA for acute stroke
85. Stroke and acute myocardial infarction in the thrombolytic era: Clinical correlates and long term prognosis
86. NMDA antagonist neurotoxicity: Mechanism and prevention
87. Synergistic effects of Citicoline and MK-801 in temporary experimental focal ischemia in rats
88. Safety and efficacy of 6 mg/kg/day tirilazad mesylate in patients with acute ischemic stroke (TESS study)
89. Piracetam as an add-on treatment to intensive speech therapy for aphasia
90. Experience with Nimodipine in aneurysmal subarachnoid haemorrhage
91. Randomized trial of tirilazad mesylate in patients with acute stroke
92. Tissue injury by free radicals and other toxic oxygen metabolites
93. Safety and efficacy of Nimodipine in resuscitation of patients outside hospital
94. Synaptic activity mediates death of hypoxic neurons
95. An open-label trial of bromocriptine in nonfluent aphasia
96. A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia
97. The effect of hyperbaric oxygen on the mental and verbal ability of stroke patients
98. The effect of hyperbaric oxygen on communication function in adults with aphasia secondary to stroke
99. GABAergic drugs and neuroplasticity after brain injury: Impact on functional recovery
100. The biologic basis for the treatment of acute stroke
101. Extracellular changes of glutamate in the peri-infarct zone: Effect of Lubeluzole
102. CDP-choline: Pharmacological and clinical review
103. The current and future use of thrombolytic therapy
104. Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology
105. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis
106. Pharmacotherapy of aphasia: A critical review
107. Restoration of speech in severe aphasia by intravenous and oral Priscol
108. Safety study of tirilazad mesylate in patients with acute stroke
109. Age-related deficits of central muscarinic cholinergic receptor function in the mouse: Partial restoration by chronic Piracetam treatment
110. The role of Piracetam in complex rehabilitation therapy of patients with residual manifestations of a cerebral stroke
111. Amphetamine accelerates recovery of locomotr function following bilateral frontal cortex ablation in cats
112. A measurement of functional communication in aphasia
113. Prevention by Eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window
114. Editorial comment
115. Clinical potential for the use of neuroprotective agents: A brief overview
116. Neuroprotection following stroke and head injury
117. A pivotal safety and efficacy trial of Cerestat (Apitaganel HCl/CNS) in acute ischemic stroke patients: Dose-escalating safety study
118. Ganglioside inhibition of glutamate-mediated protein kinase C translocation in primary cultures of cerebellar neurons
119. Konnen Hirnleistungsstorungen Medikamentos verbessert werden?
120. The Clomethiazole Acute Stroke Study (CLASS)
121. Clomethiazole Acute Stroke Study (CLASS) results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients
122. Response to amphetamine to facilitate recovery from aphasia subsequent to stroke
123. Amphetamine paired with physical therapy accelerates motor recovery after stroke: Further evidence
124. Use of amphetamine in the treatment of aphasia
125. The effect of meprobamate on recovery from aphasia
126. Die Wirkung von Piracetam bei der logopädischen Intensivtherapie von chronisch aphasischen Patienten
127. Der Aachener Aphasie Test. Differentielle Validität
128. Measurement of maximal permissible cerebral ischemia and a study of its pharmacological prolongation
129. Tirilazad reduces cortical infarction after transient by not permanent focal cerebral ischemia in rats
130. Pharmacological actions of a new TRH analogue, YM-14673, in rats subjected to cerebral ischemia and anoxia
131. Reperfusion-induced injury to the blood-braine barrier after middle cerebral artery occlusion in rats